CureVac (NASDAQ:CVAC) Trading Up 5.7% – Still a Buy?

CureVac (NASDAQ:CVAC)’s stock price shot up 5.7% during mid-day trading on Friday . The company traded as high as $4.52 and last traded at $4.47. 876,726 shares were traded during trading, a decline of 60% from the average session volume of 2,196,451 shares. The stock had previously closed at $4.23.

Analyst Ratings Changes

Separately, JMP Securities restated a “market outperform” rating and set a $16.00 price target on shares of CureVac in a report on Monday, September 16th.

CureVac Trading Down 0.5 %

The company has a 50 day moving average of $3.09 and a 200 day moving average of $3.15. The firm has a market cap of $942.53 million, a P/E ratio of 7.65, a PEG ratio of 0.24 and a beta of 2.50. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.19 and a current ratio of 6.20.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Point72 Asset Management L.P. bought a new stake in CureVac in the second quarter worth $8,237,000. Public Employees Retirement System of Ohio bought a new stake in shares of CureVac during the 3rd quarter worth about $91,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of CureVac by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 43,143 shares of the company’s stock valued at $127,000 after acquiring an additional 16,792 shares during the last quarter. Barclays PLC bought a new position in shares of CureVac in the 3rd quarter valued at approximately $67,000. Finally, Vanguard Personalized Indexing Management LLC lifted its holdings in CureVac by 99.8% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 44,044 shares of the company’s stock worth $147,000 after purchasing an additional 21,999 shares during the last quarter. Institutional investors and hedge funds own 17.26% of the company’s stock.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.